Payment overview · 2025
General Payments
$143.99
8 reported records · 7 companies
Healthcare provider profile · identity verified
Rene Vela, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALAMO, TX · NPI 1346353414
Verified facts
What the public records show
CMS Open Payments records show Rene Vela, MD received $143.99 in general payments during 2025 across 8 reported records.
Sumitomo Pharma America, Inc. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.62 | 22.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.83 | 14.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.81 | 14.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.86 | 13.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.85 | 12.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.42 | 12.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.60 | 10.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $143.99 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.62 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 228 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 157 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
157 | 54 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
228 | 72 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
115 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
260 | 71 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
64 | 22 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1412 | 452 |
| Amlodipine Besylate | Amlodipine Besylate | 1038 | 318 |
| Montelukast Sodium | Montelukast Sodium | 960 | 268 |
| Lisinopril | Lisinopril | 932 | 274 |
| Gabapentin | Gabapentin | 859 | 266 |
| Baclofen | Baclofen | 841 | 303 |
| Omeprazole | Omeprazole | 711 | 242 |
| Metformin Hcl | Metformin Hcl | 692 | 215 |
| Levothyroxine Sodium | Levothyroxine Sodium | 660 | 182 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 626 | 205 |
| Losartan Potassium | Losartan Potassium | 597 | 187 |
| Meloxicam | Meloxicam | 532 | 172 |
| Simvastatin | Simvastatin | 512 | 150 |
| Tamsulosin Hcl | Tamsulosin Hcl | 417 | 154 |
| Alendronate Sodium | Alendronate Sodium | 415 | 162 |
| Trazodone Hcl | Trazodone Hcl | 408 | 90 |
| Fluticasone Propionate | Fluticasone Propionate | 382 | 170 |
| Donepezil Hcl | Donepezil Hcl | 376 | 139 |
| Metoprolol Succinate | Metoprolol Succinate | 343 | 108 |
| Meclizine Hcl | Meclizine Hcl | 332 | 110 |
| Citalopram Hbr | Citalopram Hydrobromide | 311 | 109 |
| Naproxen | Naproxen | 306 | 130 |
| Famotidine | Famotidine | 294 | 107 |
| Azithromycin | Azithromycin | 292 | 234 |
| Furosemide | Furosemide | 287 | 101 |
| Pioglitazone Hcl | Pioglitazone Hcl | 286 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 281 | 101 |
| Ibuprofen | Ibuprofen | 280 | 123 |
| Hydrochlorothiazide | Hydrochlorothiazide | 278 | 95 |
| Dexamethasone | Dexamethasone | 273 | 212 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 272 | 83 |
| Ozempic | Semaglutide | 260 | 71 |
| Farxiga | Dapagliflozin Propanediol | 228 | 72 |
| Januvia | Sitagliptin Phosphate | 228 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 227 | 70 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 222 | 67 |
| Jardiance | Empagliflozin | 221 | 66 |
| Tramadol Hcl | Tramadol Hcl | 199 | 61 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 194 | 140 |
| Hydralazine Hcl | Hydralazine Hcl | 188 | 61 |
| Dicyclomine Hcl | Dicyclomine Hcl | 179 | 70 |
| Diclofenac Sodium | Diclofenac Sodium | 176 | 80 |
| Pravastatin Sodium | Pravastatin Sodium | 174 | 54 |
| Glipizide | Glipizide | 170 | 59 |
| Linzess | Linaclotide | 157 | 54 |
| Metformin Hcl Er | Metformin Hcl | 136 | 39 |
| Ezetimibe | Ezetimibe | 119 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 36 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 117 | 35 |
| Lorazepam | Lorazepam | 116 | 40 |
| Mounjaro | Tirzepatide | 116 | 23 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 116 | 36 |
| Glipizide Er | Glipizide | 115 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 31 |
| Glimepiride | Glimepiride | 110 | 35 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 103 | 29 |
| Pregabalin | Pregabalin | 103 | 29 |
| Amoxicillin | Amoxicillin | 102 | 89 |
| Memantine Hcl | Memantine Hcl | 102 | 37 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 100 | 83 |
| Myrbetriq | Mirabegron | 99 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 99 | 39 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 98 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 32 |
| Alprazolam | Alprazolam | 91 | 15 |
| Trulicity | Dulaglutide | 87 | 26 |
| Fluconazole | Fluconazole | 86 | 52 |
| Cefdinir | Cefdinir | 83 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 32 |
| Carvedilol | Carvedilol | 82 | 36 |
| Clindamycin Hcl | Clindamycin Hcl | 77 | 63 |
| Hydrocortisone | Hydrocortisone | 75 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 21 |
| Nifedipine Er | Nifedipine | 75 | 25 |
| Cefuroxime | Cefuroxime Axetil | 73 | 60 |
| Finasteride | Finasteride | 73 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 73 | 41 |
| Potassium Chloride | Potassium Chloride | 70 | 25 |
| Levemir Flexpen | Insulin Detemir | 69 | 29 |
| Rybelsus | Semaglutide | 64 | 22 |
| Solifenacin Succinate | Solifenacin Succinate | 64 | 21 |
| Eliquis | Apixaban | 63 | 20 |
| Clotrimazole | Clotrimazole | 62 | 43 |
| Lactulose | Lactulose | 62 | 32 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 61 | 32 |
| Terbinafine Hcl | Terbinafine Hcl | 59 | 41 |
| Constulose | Lactulose | 57 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 12 |
| Telmisartan | Telmisartan | 55 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 52 | 14 |
| Sertraline Hcl | Sertraline Hcl | 50 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 15 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 46 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 33 |
| Enalapril Maleate | Enalapril Maleate | 43 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 14 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 42 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | 12 |
| Celecoxib | Celecoxib | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Irbesartan | Irbesartan | 39 | 11 |
| Labetalol Hcl | Labetalol Hcl | 39 | 11 |
| Mupirocin | Mupirocin | 39 | 34 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Rexulti | Brexpiprazole | 36 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 29 |
| Dutasteride | Dutasteride | 35 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Cilostazol | Cilostazol | 33 | 13 |
| Gentamicin Sulfate | Gentamicin Sulfate | 33 | 21 |
| Bupropion Xl | Bupropion Hcl | 32 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Xarelto | Rivaroxaban | 31 | 12 |
| Ondansetron Odt | Ondansetron | 30 | 25 |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Kerendia | Finerenone | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | 18 |
| Cephalexin | Cephalexin | 28 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | 13 |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 19 |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 23 |
| Ofloxacin | Ofloxacin | 25 | 20 |
| Allopurinol | Allopurinol | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Enulose | Lactulose | 21 | 14 |
| Novofine 32 | Pen Needle, Diabetic | 21 | 11 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 21 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | 18 |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Sure Comfort | Syringe And Needle,insulin,1ml | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin Calcium | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Prednisolone | Prednisolone | 13 | 11 |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Clarithromycin | Clarithromycin | 12 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $143.99 · 8 records | Sumitomo Pharma America, Inc. | Cologuard Collection Kit, FARXIGA, GEMTESA, LINZESS, OTEZLA, REPATHA, TRELEGY ELLIPTA, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error